Legal & General Group Plc Takes $1.55 Million Position in Alumis Inc. $ALMS

Legal & General Group Plc acquired a new position in Alumis Inc. (NASDAQ:ALMS) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 54,930 shares of the company’s stock, valued at approximately $1,546,000.

Other institutional investors also recently bought and sold shares of the company. California State Teachers Retirement System grew its holdings in Alumis by 2,222.5% during the first quarter. California State Teachers Retirement System now owns 80,845 shares of the company’s stock valued at $1,781,000 after purchasing an additional 77,364 shares during the period. First Trust Advisors LP bought a new position in shares of Alumis in the first quarter worth about $1,456,000. The Manufacturers Life Insurance Company lifted its position in shares of Alumis by 775.6% during the 1st quarter. The Manufacturers Life Insurance Company now owns 154,634 shares of the company’s stock valued at $3,407,000 after buying an additional 136,973 shares in the last quarter. Swiss National Bank purchased a new position in shares of Alumis during the 1st quarter valued at about $2,815,000. Finally, Elmind Capital LP bought a new position in shares of Alumis during the 1st quarter valued at approximately $2,864,000.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ALMS shares. Robert W. Baird set a $27.00 target price on shares of Alumis in a report on Tuesday, September 1st. HC Wainwright raised shares of Alumis from a “neutral” rating to a “buy” rating and lowered their price target for the company from $25.00 to $15.00 in a report on Wednesday, September 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Alumis in a research note on Tuesday, July 7th. Guggenheim downgraded shares of Alumis from a “buy” rating to a “neutral” rating in a research report on Thursday. Finally, Oppenheimer lowered their target price on shares of Alumis from $55.00 to $37.00 and set an “outperform” rating on the stock in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Alumis currently has an average rating of “Moderate Buy” and a consensus price target of $33.27.

Alumis News Summary

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: HC Wainwright upgraded its rating on Alumis. The upgrade helped support an earlier rebound in the shares, although its effect was subsequently overshadowed by the lupus-trial news. Alumis Stock Rating Upgraded by HC Wainwright
• Positive Sentiment: Alumis will participate in several September investor conferences. These events could give management an opportunity to explain the clinical results, discuss its broader pipeline and outline its strategy for using biomarker data to identify potentially responsive lupus patients. Alumis to Participate in Upcoming September Investor Conferences
• Neutral Sentiment: Options activity was unusually high. Elevated options trading indicates increased investor positioning and volatility following the clinical announcement, but it does not establish a clear directional outlook. Alumis Target of Unusually Large Options Trading
• Negative Sentiment: Alumis’ Phase 2b lupus study missed its key endpoints. The mixed data for the company’s lead SLE treatment raised concerns about the drug’s efficacy and commercial prospects, triggering a sharp decline in the stock. Management’s potential biomarker-based development strategy may preserve a path forward, but it also adds uncertainty and could require additional clinical work. Alumis Lead Lupus Drug Missed Phase 2b Trial Endpoints
• Negative Sentiment: Guggenheim downgraded Alumis from Buy to Neutral after the trial setback. The downgrade reflects reduced confidence in the lupus program and likely contributed to continued selling pressure. Additional analyst commentary has focused on the implications of the clinical miss for valuation and the company’s pipeline. Alumis Downgraded at Guggenheim

Alumis Stock Performance

Shares of ALMS opened at $11.10 on Monday. The business’s 50 day moving average is $25.33 and its 200 day moving average is $24.60. The company has a market capitalization of $1.44 billion, a PE ratio of -2.88 and a beta of -0.81. Alumis Inc. has a 12-month low of $3.76 and a 12-month high of $31.35.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.34). Alumis had a negative return on equity of 93.15% and a negative net margin of 5,933.46%.The business had revenue of $1.66 million during the quarter, compared to analysts’ expectations of $3.65 million. Equities research analysts predict that Alumis Inc. will post -2.95 earnings per share for the current year.

Insider Transactions at Alumis

In related news, insider Roy C. Hardiman sold 2,692 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total transaction of $70,988.04. Following the completion of the transaction, the insider directly owned 207,746 shares of the company’s stock, valued at approximately $5,478,262.02. This trade represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Sanam Pangali sold 5,000 shares of Alumis stock in a transaction on Monday, July 6th. The shares were sold at an average price of $28.00, for a total transaction of $140,000.00. Following the completion of the sale, the insider owned 11,111 shares in the company, valued at approximately $311,108. This represents a 31.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 19,953 shares of company stock valued at $534,311. 33.70% of the stock is owned by corporate insiders.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.